C2N Diagnostics Employee Directory
Biotechnology ResearchMissouri, United States51-200 Employees
C2N Diagnostics is a biotechnology research company focused on mechanism-based approaches to preventing or slowing neurological disorders and improving patient care through accessible, cost-effective blood-based brain health tests. Its lead product, PrecivityAD, is a mass spectrometry–based blood test conducted in a CLIA-certified lab that measures biomarkers such as Aβ42, Aβ40, and apolipoprotein E isoforms. The test supports clinical evaluation by predicting brain amyloid plaques as seen on PET scans, rather than serving as an Alzheimer's diagnosis, and is ordered through healthcare providers with regulatory recognition including FDA Breakthrough Device Designation (2019) and CE marking. Based in St. Louis, Missouri, the mid-sized biotechnology research company has pursued international partnerships to expand brain health diagnostics, including collaborations in Australia and Brazil. In 2023, it launched the PrecivityAD2 blood tests for patients aged 60 and older, reflecting ongoing product development to broaden its clinical reach.
1-888-653-2347 
support@leadiq.com 
